SCIENTIFIC
PUBLICATION
Results from the study showed significant positive effects for players treated with PolarCap (intervention group) in comparison with non-treated players (control group), in relation to shortened recovery time from a concussion, and immediate relief of symptoms. Most interestingly, the study found that long-term absence (3 weeks or more) was greatly reduced among treated players (by almost 80%).
In September 2022 the study was peer-reviewed and accepted to be published by the Journal of Neurotrauma.
ADDRESS
PolarCool AB
Medicon Village
223 81 Lund
The table shows the percentage of players absent due to concussion, and the correlating return to play days, for players who were treated with PolarCap® System compared to non-treated players.
All differences in favor of the treatment group are statistically significant (p<0.05).
5 YEAR POLARCAP® STUDY RETURN TO PLAY TABLE | 132 CASES
POLARCAP® IN THE
SWEDISH HOCKEY LEAGUE (SHL)
Due to the positive results shown in the SHL study, with the support of the Swedish Hockey Players Union SICO, a PolarCap® System has been available at every SHL game, since the start of the 2020/2021 season.
Since the founding of PolarCool, a key focus has been to conduct and support studies evaluating the clinical effects of the PolarCap® System in relation to the treatment of concussion and sub-concussive repetitive blows to the head.
5 YEAR POLARCAP® STUDY PUBLISHED IN THE JOURNAL OF NEUROTRAUMA
As a treatment for concussion, PolarCap® has been clinically evaluated in a 5-year study in partnership between Lund University and the Swedish Ice Hockey League (SHL) where a total of 19 Swedish professional ice hockey teams participated over 5 seasons. The study was initiated in 2016 and was led by Professor Niklas Marklund.
The study is titled: ‘Shorter recovery time in concussed elite ice hockey players by early head-and neck cooling - a clinical trial.'
